De novo synthesis of diacylglycerol in endothelium may mediate the association between PAI-1 and the insulin resistance syndrome

Medical Hypotheses

Volumn 64, Issue 2, 2005, Pages 388-393

  McCarty, Mark F ^a,b  

^a NutriGuard Research   (United States)

^b Pantox Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIACYLGLYCEROL; GEMFIBROZIL; HEPARIN; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; TRANSCRIPTION FACTOR SP1; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; REVIEW; VASCULAR ENDOTHELIUM;

EID: 11144342329     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.03.038     Document Type: Article

References (88)

1. McCarty M.F. Does postprandial storage of triglycerides in endothelial cells contribute to the endothelial dysfunction associated with insulin resistance and fatty diets? Med. Hypotheses. 61:2003;167-172
2. McCarty MF. AMPK activation as a strategy for reversing the endothelial lipotoxicity underlying the increased vascular risk associated with insulin resistance syndrome. Med Hypoth 2004; in press
3. Balletshofer B.M., Rittig K., Volk A., Maerker E., Jacob S., Rett K., et al. Impaired non-esterified fatty acid suppression is associated with endothelial dysfunction in insulin resistant subjects. Horm. Metab. Res. 33:2001;428-431
4. Sarabi M., Fugmann A., Karlstrom B., Berne C., Lithell H., Lind L. An ordinary mixed meal transiently impairs endothelium-dependent vasodilation in healthy subjects. Acta. Physiol. Scand. JID - 0370362. 172:2001;107-113
5. Inoguchi T., Li P., Umeda F., Yu H.Y., Kakimoto M., et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 49:2000;1939-1945
6. Baron A.D. Insulin resistance and vascular function. J. Diabetes Complicat. 16:2002;92-102
7. Ruderman N.B., Cacicedo J.M., Itani S., Yagihashi N., Saha A.K., et al. Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem. Soc. Trans. 31:2003;202-206
8. Michell B.J., Chen Z., Tiganis T., Stapleton D., Katsis F., Power D.A., et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J. Biol. Chem. 276:2001;17625-17628
9. Pieper G.M., Riaz u.H. Activation of nuclear factor-κB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. J. Cardiovasc. Pharmacol. 30:1997;528-532
10. Sugiyama S., Kugiyama K., Ogata N., Doi H., Ota Y., et al. Biphasic regulation of transcription factor nuclear factor-κB activity in human endothelial cells by lysophosphatidylcholine through protein kinase C-mediated pathway. Arterioscler. Thromb. Vasc. Biol. 18:1998;568-576
11. Park J.Y., Kim Y.M., Song H.S., Park K.Y., Kim Y.M., Kim M.S., et al. Oleic acid induces endothelin-1 expression through activation of protein kinase C and NF-κ B. Biochem. Biophys. Res. Commun. 303:2003;891-895
12. Juhan-Vague I., Alessi M.C., Mavri A., Morange P.E. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J. Thromb. Haemost. 1:2003;1575-1579
13. Haffner S.M. Insulin resistance, inflammation, and the prediabetic state. Am. J. Cardiol. 92:2003;18J-26J
14. Huber K., Christ G., Wojta J., Gulba D. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. Thromb. Res. 103(Suppl 1):2001;S7-S19
15. Huber K. Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease. J. Thromb. Thrombolys. 11:2001;183-193
16. Tsikouris J.P., Suarez J.A., Meyerrose G.E. Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents. J. Clin. Pharmacol. 42:2002;1187-1199
17. Crowther M.A., Roberts J., Roberts R., Johnston M., Stevens P., Skingley P., et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb. Haemost. 85:2001;390-394
18. Folsom A.R., Cushman M., Heckbert S.R., Rosamond W.D., Aleksic N. Prospective study of fibrinolytic markers and venous thromboembolism. J. Clin. Epidemiol. 56:2003;598-603
19. Francis C.W. Plasminogen activator inhibitor-1 levels and polymorphisms. Arch. Pathol. Lab. Med. 126:2002;1401-1404
20. Juhan-Vague I., Alessi M.C. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb. Haemost. 78:1997;656-660
21. Festa A., D'Agostino R. Jr., Rich S.S., Jenny N.S., Tracy R.P., Haffner S.M. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation. 107:2003;2422-2427
22. Alessi M.C., Juhan-Vague I., Kooistra T., Declerck P.J., Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb. Haemost. 60:1988;491-494
23. Nordt T.K., Sawa H., Fujii S., Bode C., Sobel B.E. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo. J. Mol. Cell Cardiol. 30:1998;1535-1543
24. Grenett H.E., Benza R.L., Li X.N., Aikens M.L., Grammer J.R., Brown S.L., et al. Expression of plasminogen activator inhibitor type I in genotyped human endothelial cell cultures: genotype-specific regulation by insulin. Thromb. Haemost. 82:1999;1504-1509
25. Landin K., Tengborn L., Chmielewska J., Von Schenck H., Smith U. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb. Haemost. 65:1991;130-133
26. Bastard J.P., Bruckert E., Robert J.J., Ankri A., Grimaldi A., Jardel C., et al. Are free fatty acids related to plasma plasminogen activator inhibitor 1 in android obesity? Int. J. Obes. Relat. Metab. Disord. 19:1995;836-838
27. Lormeau B., Aurousseau M.H., Valensi P., Paries J., Attali J.R. Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients. Metabolism. 46:1997;1074-1079
28. Jain S.K., Nagi D.K., Slavin B.M., Lumb P.J., Yudkin J.S. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet. Med. 10:1993;27-32
29. Calles-Escandon J., Mirza S.A., Sobel B.E., Schneider D.J. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes. 47:1998;290-293
30. Krebs M., Geiger M., Polak K., Vales A., Schmetterer L., Wagner O.F., et al. Increased plasma levels of plasminogen activator inhibitor-1 and soluble vascular cell adhesion molecule after triacylglycerol infusion in man. Thromb. Haemost. 90:2003;422-428
31. Schneider D.J., Sobel B.E. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids. Coron. Artery Dis. 7:1996;813-817
32. Chen Y., Billadello J.J., Schneider D.J. Identification and localization of a fatty acid response region in the human plasminogen activator inhibitor-1 gene. Arterioscler. Thromb. Vasc. Biol. 20:2000;2696-2701
33. Chen Y., Schneider D.J. The independence of signaling pathways mediating increased expression of plasminogen activator inhibitor type 1 in HepG2 cells exposed to free fatty acids or triglycerides. Int. J. Exp. Diabetes Res. 3:2002;109-118
34. Chen Y., Sobel B.E., Schneider D.J. Effect of fatty acid chain length and thioesterification on the augmentation of expression of plasminogen activator inhibitor-1. Nutr. Metab. Cardiovasc. Dis. 12:2002;325-330
35. Banfi C., Eriksson P., Giandomenico G., Mussoni L., Sironi L., Hamsten A., et al. Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway. Diabetes. 50:2001;1522-1530
36. Vulin A.I., Stanley F.M. A Forkhead/winged helix-related transcription factor mediates insulin-increased plasminogen activator inhibitor-1 gene transcription. J. Biol. Chem. 277:2002;20169-20176
37. Kietzmann T., Samoylenko A., Roth U., Jungermann K. Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Blood. 101:2003;907-914
38. Dresner A., Laurent D., Marcucci M., Griffin M.E., Dufour S., Cline G.W., et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 103:1999;253-259
39. Griffin M.E., Marcucci M.J., Cline G.W., Bell K., Barucci N., Lee D., et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes. 48:1999;1270-1274
40. Yu C., Chen Y., Cline G.W., Zhang D., Zong H., Wang Y., et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277:2002;50230-50236
41. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes. 47:1998;859-866
42. Grulich-Henn J., Muller-Berghaus G. Regulation of endothelial tissue plasminogen activator and plasminogen activator inhibitor type 1 synthesis by diacylglycerol, phorbol ester, and thrombin. Blut. 61:1990;38-44
43. Konkle B.A., Kollros P.R., Kelly M.D. Heparin-binding growth factor-1 modulation of plasminogen activator inhibitor-1 expression. Interaction with cAMP and protein kinase C-mediated pathways. J. Biol. Chem. 265:1990;21867-21873
44. Kooistra T., Bosma P.J., Toet K., Cohen L.H., Griffioen M., et al. Role of protein kinase C and cyclic adenosine monophosphate in the regulation of tissue-type plasminogen activator, plasminogen activator inhibitor-1, and platelet-derived growth factor mRNA levels in human endothelial cells. Possible involvement of proto-oncogenes c-jun and c-fos. Arterioscler. Thromb. 11:1991;1042-1052
45. Slivka S.R., Loskutoff D.J. Regulation of type I plasminogen activator inhibitor synthesis by protein kinase C and cAMP in bovine aortic endothelial cells. Biochim. Biophys. Acta. 1094:1991;317-322
46. Zidovetzki R., Wang J.L., Kim J.A., Chen P., Fisher M., Hofman F.M. Endothelin-1 enhances plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C-dependent pathway. Arterioscler. Thromb. Vasc. Biol. 19:1999;1768-1775
47. Feener E.P., Northrup J.M., Aiello L.P., King G.L. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J. Clin. Invest. 95:1995;1353-1362
48. Shi G.Y., Wang S.J., Chang B., Tasi C.F., Lin M.T., Chang W.C., et al. Regulation of plasminogen activator inhibitor activity by plasmin in endothelial cells. Thromb. Res. 81:1996;75-84
49. Banfi C., Mussoni L., Ris P., Cattaneo M.G., Vicentini L., Battaini F., et al. Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells. Circ. Res. 85:1999;208-217
50. Ren S., Shatadal S., Shen G.X. Protein kinase C-beta mediates lipoprotein-induced generation of PAI-1 from vascular endothelial cells. Am. J. Physiol. Endocrinol. Metab. 278:2000;E656-E662
51. Goldberg H.J., Whiteside C.I., Fantus I.G. The hexosamine pathway regulates the plasminogen activator inhibitor-1 gene promoter and Sp1 transcriptional activation through protein kinase C-beta I and -delta. J. Biol. Chem. 277:2002;33833-33841
52. Zidovetzki R., Chen P., Fisher M., Hofman F.M., Faraci F.M. Nicotine increases plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C-associated pathway. Stroke. 30:1999;651-655
53. Knudsen H., Olesen T., Riccio A., Ungaro P., Christensen L., Andreasen P.A. A common response element mediates differential effects of phorbol esters and forskolin on type-1 plasminogen activator inhibitor gene expression in human breast carcinoma cells. Eur. J. Biochem. 220:1994;63-74
54. Vague P., Raccah D., Scelles V. Hypofibrinolysis and the insulin resistance syndrome. Int. J. Obes. Relat. Metab. Disord. 19(Suppl 1):1995;S11-S15
55. Mussoni L., Mannucci L., Sirtori M., Camera M., Maderna P., Sironi L., et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler. Thromb. 12:1992;19-27
56. Eriksson P., Nilsson L., Karpe F., Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 18:1998;20-26
57. Nordt T.K., Kornas K., Peter K., Fujii S., Sobel B.E., Kubler W., et al. Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors. Circulation. 95:1997;677-683
58. Nilsson L., Takemura T., Eriksson P., Hamsten A. Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. Arterioscler. Thromb. Vasc. Biol. 19:1999;1577-1581
59. Nordt T.K., Lutzi S., Ruef J., Peter K., Klar E., Kubler W., et al. Attenuation by fibrates of plasminogen activator inhibitor type-1 expression in human arterial smooth muscle cells. Thromb. Haemost. 86:2001;1305-1313
60. Broijersen A., Eriksson M., Wiman B., Angelin B., Hjemdahl P. Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. Arterioscler. Thromb. Vasc. Biol. 16:1996;511-516
61. Asplund-Carlson A. Effects of gemfibrozil therapy on glucose tolerance, insulin sensitivity and plasma plasminogen activator inhibitor activity in hypertriglyceridaemia. J. Cardiovasc. Risk. 3:1996;385-390
62. Kockx M., de Maat M.P., Knipscheer H.C., Kastelein J.J., Kluft C., Princen H.M., et al. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients. Thromb. Haemost. 78:1997;1167-1172
63. Hamsten A., Syvanne M., Silveira A., Luong L.A., Nieminen M.S., Humphries S., et al. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy. Thromb. Haemost. 83:2000;397-403
64. Lundgren C.H., Brown S.L., Nordt T.K., Sobel B.E., Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation. 93:1996;106-110
65. Alessi M.C., Peiretti F., Morange P., Henry M., Nalbone G., Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 46:1997;860-867
66. Eriksson P., Reynisdottir S., Lonnqvist F., Stemme V., Hamsten A., Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia. 41:1998;65-71
67. Cigolini M., Tonoli M., Borgato L., Frigotto L., Manzato F., Zeminian S., et al. Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha? Atherosclerosis. 143:1999;81-90
68. Alessi M.C., Morange P., Juhan-Vague I. Fat cell function and fibrinolysis. Horm. Metab. Res. 32:2000;504-508
69. Sakamoto T., Woodcock-Mitchell J., Marutsuka K., Mitchell J.J., Sobel B.E., Fujii S. TNF-alpha and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes. Am. J. Physiol. 276:1999;C1391-C1397
70. Morange P.E., Aubert J., Peiretti F., Lijnen H.R., Vague P., Verdier M., et al. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes. 48:1999;890-895
71. Harte A.L., McTernan P.G., McTernan C.L., Smith S.A., Barnett A.H., Kumar S. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. Diabetes Obes. Metab. 5:2003;302-310
72. Yudkin J.S., Coppack S.W., Bulmer K., Rawesh A., Mohamed-Ali V. Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo. Thromb. Res. 96:1999;1-9
73. Yudkin J.S., Kumari M., Humphries S.E., Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 148:2000;209-214
74. McCarty M.F. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. Med. Hypotheses. 52:1999;465-477
75. Heinrich P.C., Horn F., Graeve L., Dittrich E., Kerr I., Muller-Newwen G., et al. Interleukin-6 and related cytokines: effect on the acute phase reaction. Z. Ernahrungswiss. 37(Suppl 1):1998;43-49
76. Arndt A., Murphy P., Hart D.A. Human HuH-7 hepatoma cells express urokinase and plasminogen activator inhibitor-1: identification, characterization and regulation by inflammatory mediators. Biochim. Biophys. Acta. 1138:1992;149-156
77. Healy A.M., Gelehrter T.D. Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response. J. Biol. Chem. 269:1994;19095-19100
78. Koike C., Hayakawa Y., Niiya K., Sakuragawa N., Sasaki H. The production of heparin cofactor II is not regulated by inflammatory cytokines in human hepatoma cells: comparison with plasminogen activator inhibitor type-1. Thromb. Haemost. 75:1996;298-302
79. Dong J., Fujii S., Goto D., Furumoto T., Kaneko T., Zaman T.A., et al. Increased expression of plasminogen activator inhibitor-1 by mediators of the acute phase response: a potential progenitor of vasculopathy in hypertensives. Hypertens. Res. 26:2003;723-729
80. Podor T.J., Jirik F.R., Loskutoff D.J., Carson D.A., Lotz M. Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6. Ann. NY Acad. Sci. 557:1989;374-385
81. Kockx M., Leenen R., Seidell J., Princen H.M., Kooistra T. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss. Thromb. Haemost. 82:1999;1490-1496
82. Charles M.A., Morange P., Eschwege E., Andre P., Vague P., Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care. 21:1998;1967-1972
83. Kato K., Yamada D., Midorikawa S., Sato W., Watanabe T. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus. Metabolism. 49:2000;662-665
84. Kruszynska Y.T., Yu J.G., Olefsky J.M., Sobel B.E. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes. 49:2000;633-639
85. Velazquez E.M., Mendoza S.G., Wang P., Glueck C.J. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism. 46:1997;454-457
86. Seli E., Duleba A.J. Should patients with polycystic ovarian syndrome be treated with metformin? Hum. Reprod. 17:2002;2230-2236
87. Grant P.J. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab. 29:2003;6S44-6S52
88. Mehrabian M., Peter J.B., Barnard R.J., Lusis A.J. Dietary regulation of fibrinolytic factors. Atherosclerosis. 84:1990;25-32